TACE New Cancer Region Is Not Failure - TACE + Sorafenib Should Be Continued Even After New Cancer

TACE New Cancer Region Is Not Failure - TACE + Sorafenib Should Be Continued Even After New Cancer

186 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Masatoshi Kudo, MD from Kindai University, Japan discusses TACE new cancer region is not failure and TACE + Sorafenib should be continued even after new cancer at the 2018 Gastrointestinal Cancers Symposium.
Up Next Autoplay